Loading…
Based on limited metadata, this FDA Warning Letter issued to Bella Pharmaceuticals, Inc. on February 11, 2019, concerns drug manufacturing or marketing violations, though the specific nature of the violations cannot be determined as the subject line is unavailable. The warning falls under FDA's drug product regulation authority, though the specific issuing office is not identified in the available metadata. Without access to the full letter text, the precise regulatory violations and their scope cannot be summarized further.